title: [Genetic variants in C5 and poor response to eculizumab].
abstract: This review summarizes the presentation entitled "Genetic variants in C5 and poor response to eculizumab" (N Engl J Med. 2014; 370: 632-639), given at Symposium 3 entitled "Basic and clinical topics on red blood cell membrane", during the 76th Annual Meeting of the Japanese Society of Hematology. The molecular basis for the poor response to eculizumab in Japanese patients is unclear. Of 345 Japanese patients with PNH who received eculizumab, 11 showed a poor response. All 11 had a single missense C5 heterozygous mutation, c.2654G→A, which predicts the polymorphism p.Arg885His. The prevalence of this mutation among patients with PNH (3.2%) was similar to that in healthy Japanese people (3.5%). This polymorphism was also identified in a Han Chinese population. Non-mutant and mutant C5 both caused hemolysis in vitro, but only non-mutant C5 bound to and was blocked by eculizumab. In vitro hemolysis due to non-mutant and mutant C5 was completely blocked by N19-8, a monoclonal antibody that binds to a different site on C5 than does eculizumab. The functional capacity of the C5 polymorphism p. Arg885His, together with its failure to undergo blockade by eculizumab, accounts for the poor response to this agent of patients who carry this mutation.
authors.affiliation: Osaka University Graduate School of Medicine, Department of Hematology and Oncology.
authors.forename: Jun-Ichi
authors.initials: J
authors.lastname: Nishimura
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D003182:Complement C5 / Q000235:genetics*; D006457:Hemoglobinuria, Paroxysmal / Q000188:drug therapy; D006461:Hemolysis; D006801:Humans; D009154:Mutation; D011110:Polymorphism, Genetic; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D003182:Complement C5; C481642:eculizumab